leukotriene antagonists

Summary

Summary: A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level.

Top Publications

  1. ncbi Leukotrienes
    Marc Peters-Golden
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor 48109 5642, USA
    N Engl J Med 357:1841-54. 2007
  2. ncbi Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial
    Crichton F Ramsay
    Department of Respiratory Medicine, Norfolk and Norwich University Hospital, Norwich, UK
    Thorax 66:7-11. 2011
  3. pmc Cysteinyl leukotriene receptor antagonists inhibit tumor metastasis by inhibiting capillary permeability
    Masako Nozaki
    Department of Clinical Pharmacology, Tokai University School of Medicine, Kanagawa, Japan
    Keio J Med 59:10-8. 2010
  4. ncbi Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT)
    P E Korenblat
    Washington University, St Louis, Missouri, USA
    Ann Allergy Asthma Immunol 84:217-25. 2000
  5. ncbi Leukotriene D4 stimulates the migration but not proliferation of endothelial cells mediated by the cysteinyl leukotriene cyslt(1) receptor via the extracellular signal-regulated kinase pathway
    Yu Mei Yuan
    Department of Pharmacology, School of Medicine, Zhejiang University, China
    J Pharmacol Sci 109:285-92. 2009
  6. ncbi UVB radiation induces apoptosis in keratinocytes by activating a pathway linked to "BLT2-reactive oxygen species"
    Ho Cheol Ryu
    School of Life Sciences and Biotechnology, Korea University, Seoul, Korea
    J Invest Dermatol 130:1095-106. 2010
  7. ncbi Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids
    J C Virchow
    Department of Pneumology, University Medical Clinic Freiburg, Germany and AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom
    Am J Respir Crit Care Med 162:578-85. 2000
  8. ncbi Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy
    Baldur Sveinbjörnsson
    Childhood Cancer Research Unit, Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden
    FASEB J 22:3525-36. 2008
  9. ncbi Novel therapies in asthma: leukotriene antagonists, biologic agents, and beyond
    Eric S Papierniak
    Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL 32610 0225, USA
    Am J Ther 20:79-103. 2013
  10. ncbi Characterization of the human cysteinyl leukotriene CysLT1 receptor
    K R Lynch
    Department of Pharmacology, University of Virginia Health Sciences Center, Charlottesville 22908, USA
    Nature 399:789-93. 1999

Research Grants

Detail Information

Publications221 found, 100 shown here

  1. ncbi Leukotrienes
    Marc Peters-Golden
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor 48109 5642, USA
    N Engl J Med 357:1841-54. 2007
  2. ncbi Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial
    Crichton F Ramsay
    Department of Respiratory Medicine, Norfolk and Norwich University Hospital, Norwich, UK
    Thorax 66:7-11. 2011
    ..Although leukotriene receptor antagonists have an established role in the management of patients with chronic asthma, their efficacy in an acute asthma exacerbation is not fully known...
  3. pmc Cysteinyl leukotriene receptor antagonists inhibit tumor metastasis by inhibiting capillary permeability
    Masako Nozaki
    Department of Clinical Pharmacology, Tokai University School of Medicine, Kanagawa, Japan
    Keio J Med 59:10-8. 2010
    ..These results show that pranlukast can inhibit tumor cell migration through both the brain and peripheral capillaries, whereas montelukast inhibits tumor cell migration only in the peripheral capillaries...
  4. ncbi Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT)
    P E Korenblat
    Washington University, St Louis, Missouri, USA
    Ann Allergy Asthma Immunol 84:217-25. 2000
    ..The Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT), evaluated zafirlukast in a wide spectrum of patients from a variety of clinical practices...
  5. ncbi Leukotriene D4 stimulates the migration but not proliferation of endothelial cells mediated by the cysteinyl leukotriene cyslt(1) receptor via the extracellular signal-regulated kinase pathway
    Yu Mei Yuan
    Department of Pharmacology, School of Medicine, Zhejiang University, China
    J Pharmacol Sci 109:285-92. 2009
    ..Our findings indicate that LTD(4) stimulates the CysLT(1) receptor-mediated migration of endothelial cells; this may be regulated by the ERK1/2 pathway...
  6. ncbi UVB radiation induces apoptosis in keratinocytes by activating a pathway linked to "BLT2-reactive oxygen species"
    Ho Cheol Ryu
    School of Life Sciences and Biotechnology, Korea University, Seoul, Korea
    J Invest Dermatol 130:1095-106. 2010
    ..Taken together, our results demonstrate that a "BLT2-Nox1"-linked pathway has a crucial role in UVB-induced ROS generation and mediates apoptosis in human keratinocytes...
  7. ncbi Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids
    J C Virchow
    Department of Pneumology, University Medical Clinic Freiburg, Germany and AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom
    Am J Respir Crit Care Med 162:578-85. 2000
    ....
  8. ncbi Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy
    Baldur Sveinbjörnsson
    Childhood Cancer Research Unit, Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden
    FASEB J 22:3525-36. 2008
    ..These findings provide new insights into the pathobiology of neuroblastoma, and the use of leukotriene pathway inhibitors as a novel adjuvant therapy for children with neuroblastoma warrants further consideration...
  9. ncbi Novel therapies in asthma: leukotriene antagonists, biologic agents, and beyond
    Eric S Papierniak
    Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL 32610 0225, USA
    Am J Ther 20:79-103. 2013
    ..A brief discussion of other drugs, such as those developed for unrelated conditions and subsequently examined as potential asthma therapies, is included...
  10. ncbi Characterization of the human cysteinyl leukotriene CysLT1 receptor
    K R Lynch
    Department of Pharmacology, University of Virginia Health Sciences Center, Charlottesville 22908, USA
    Nature 399:789-93. 1999
    ..In normal human lung, expression of the CysLT1-receptor mRNA was confined to smooth muscle cells and tissue macrophages. Finally, we mapped the human CysLT1-receptor gene to the X chromosome...
  11. ncbi The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in Japanese patients
    Mitsuru Adachi
    First Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan
    J Asthma 49:649-56. 2012
    ..However, current treatment for acute asthma provides inadequate benefit for some patients. We evaluated the efficacy and safety of IV montelukast added to standard therapy in Japanese patients with acute asthma exacerbations...
  12. ncbi Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma
    A Y Wu
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, China
    Clin Exp Allergy 33:359-66. 2003
    ..We investigated the effect of high-dose montelukast (MK), a selective cysteinyl leukotriene receptor 1 antagonist, on mediators of airway inflammation...
  13. pmc Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children
    Bhupendrasinh F Chauhan
    Clinical Research Unit of Childhood Asthma, Chu Sainte Justine hospital Research Centre, 3175, Cote Sainte Catherine, Montreal, Canada
    Cochrane Database Syst Rev 5:CD002314. 2012
    ..Anti-leukotrienes (5-lipoxygenase inhibitors and leukotriene receptors antagonists) serve as alternative monotherapy to inhaled corticosteroids (ICS) in the management of recurrent and/or chronic asthma in adults and children...
  14. ncbi A randomized controlled trial of intravenous montelukast in acute asthma
    Carlos A Camargo
    Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Am J Respir Crit Care Med 167:528-33. 2003
    ..We conclude that intravenous montelukast in addition to standard therapy causes rapid benefit and is well tolerated in adults with acute asthma...
  15. ncbi Short-term effects of montelukast in stable patients with moderate to severe COPD
    Pinar Celik
    Department of Chest Disease, Celal Bayar University Medicine School, Manisa, Turkey
    Respir Med 99:444-50. 2005
    ....
  16. ncbi Comparison of glucocorticoid and cysteinyl leukotriene receptor antagonist treatments in an experimental model of chronic airway inflammation in guinea-pigs
    E A Leick-Maldonado
    Department of Medicine, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil
    Clin Exp Allergy 34:145-52. 2004
    ..In the present study, we evaluated the effects of treatment with dexamethasone or montelukast on eosinophil and mononuclear cell recruitment in an experimental model of allergen-induced chronic airway inflammation in guinea-pigs (GP)...
  17. pmc Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma
    Stephen C Lazarus
    University of California, San Francisco, 505 Parnassus Avenue, M 1083, San Francisco, CA 94143 0111, USA
    Am J Respir Crit Care Med 175:783-90. 2007
    ..One-quarter to one-third of individuals with asthma smoke, which may affect response to therapy and contribute to poor asthma control...
  18. ncbi Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma?
    Tuomas Jartti
    Department of Pediatrics, Turku University Hospital, Kiinamyllynkatu 4 6, 20520 Turku, Finland
    Eur J Pediatr 167:731-6. 2008
    ..If montelukast is selected as a monotherapy and asthma is not adequately controlled within 4-6 weeks, the treatment should be discontinued and the preferred medication initiated...
  19. ncbi History and future perspectives of treating asthma as a systemic and small airways disease
    L Bjermer
    Department of Lung Medicine, University Hospital, Trondheim, Norway
    Respir Med 95:703-19. 2001
    ..The leukotriene receptor antagonists and anti-IgE monoclonal antibodies are examples of such therapies and the emergence of other new strategies is awaited...
  20. ncbi A randomized open-label comparative study of montelukast versus theophylline added to inhaled corticosteroid in asthmatic children
    Naomi Kondo
    Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan
    Allergol Int 55:287-93. 2006
    ..The efficacy and the safety of montelukast added to low-dose ICS therapy were compared with those of sustained-release theophylline added to low-dose ICS therapy in asthmatic children in the present study...
  21. ncbi Comparative efficacy of inhaled corticosteroids and antileukotriene drugs in asthma
    L J Smith
    Northwestern University, Office of Clinical Research and Training, Division of Pulmonary and Critical Care Medicine, 710 N Lake Shore Drive, Chicago, IL 60611, USA
    BioDrugs 15:239-49. 2001
    ..Antileukotriene drugs should be considered as add-on therapy, especially in view of their possible complementary effects on reducing airway inflammation...
  22. ncbi Leukotriene D(4) enhances the function of endothelin-1-primed fibroblasts
    Shuko Tokuriki
    Department of Pediatrics, Faculty of Medical Sciences, University of Fukui, 23 3 Shimoaizuki, Matsuoka, Yoshida gun, Fukui, Japan
    Clin Immunol 125:88-94. 2007
    ..Our data suggested that LTD(4) may act as a precipitating factor during ET-1-mediated airway remodeling and that CysLT1 receptor antagonists may have a role in preventing aberrant extracellular matrix degradation...
  23. ncbi The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model
    M Hamdi Muz
    Department of Chest Diseases, Elazi State Hospital, Elazig, Turkey
    Exp Mol Med 38:109-18. 2006
    ..Lower dose of CysLT1 receptor antagonism has a significant anti-inflammatory effect on allergen-induced lung inflammation and fibrosis but not airway smooth muscle hypertrophy in an animal model of asthma...
  24. ncbi Effect of the cysteinyl leukotriene antagonist pranlukast on transendothelial migration of eosinophils
    Makoto Nagata
    Department of Respiratory Medicine, Saitama Medical School, Japan
    Int Arch Allergy Immunol 137:2-6. 2005
    ..The present study evaluates whether pranlukast (an LTRA) modifies eosinophil TEM in response to chemoattractants including PAF and C-C chemokines...
  25. ncbi Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis
    Masahide Matsuyama
    Department of Urology, Osaka City University Hospital, Osaka 545 8585, Japan
    Oncol Rep 18:99-104. 2007
    ..In conclusion, CysLT1R is induced in PC, and the results suggest that CysLT1R antagonist may mediate potent anti-proliferative effects of PC cells. Thus, the target of CysLT1R may become a new therapy in the treatment of PC...
  26. ncbi A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICA
    Iwona Stelmach
    Department of Pediatrics and Allergy, M Curie Hospital, Zgierz, Poland
    J Allergy Clin Immunol 109:257-63. 2002
    ..Anti-inflammatory properties of leukotriene modifiers and their effect on bronchial hyperresponsiveness have not been studied in children with asthma...
  27. ncbi Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age
    Peter Creticos
    John Hopkins Asthma and Allergy Center, Baltimore, Maryland 21442, USA
    Ann Allergy Asthma Immunol 88:401-9. 2002
    ..There are limited published data describing the relative efficacy of available treatment options in younger versus older patients with persistent asthma...
  28. ncbi Oral montelukast treatment of preschool-aged children with acute asthma
    Koray Harmanci
    Faculty of Medicine, Department of Pediatric Allergy and Asthma, Gazi University, Ankara, Turkey
    Ann Allergy Asthma Immunol 96:731-5. 2006
    ..Although the use of leukotriene receptor antagonists has been recommended in the treatment of chronic asthma, no guidelines are available regarding their use in the treatment of acute asthma...
  29. ncbi A phase I randomized, placebo-controlled, dose-exploration study of single-dose inhaled montelukast in patients with chronic asthma
    George Philip
    Merck Research Laboratories, North Wales, PA 19454, USA
    J Asthma 47:1078-84. 2010
    ..The efficacy of oral montelukast has been well established in asthma and allergic rhinitis in adults and children. The purpose of this study was to evaluate dose-related bronchodilation and tolerability of inhaled montelukast...
  30. ncbi Viral-induced wheezing episodes in preschool children: approaches to therapy
    Leonard B Bacharier
    Department of Pediatrics, Division of Allergy, Immunology, and Pulmonary Medicine, Washington University School of Medicine, St Louis Children s Hospital, St Louis, Missouri 63110, USA
    Curr Opin Pulm Med 16:31-5. 2010
    ..The high prevalence of wheezing illnesses in the preschool age group and the heterogeneity of wheezing phenotypes early in life combine to present significant challenges in the clinical management of this problem...
  31. pmc Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation
    S A Green
    Merck Research Laboratories, Rahway, NJ, USA
    Thorax 59:100-4. 2004
    ..Activation of leukotriene pathways is accompanied by rises in detectable urinary levels of leukotriene E4 (LTE4). The relationship between urinary LTE4 levels and factors associated with acute asthma has not been determined...
  32. ncbi Chemotaxis and transendothelial migration of CD34(+) hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1
    F Bautz
    Department of Medicine II, , , Germany
    Blood 97:3433-40. 2001
    ..This would be a first physiologic effect of cysteinyl leukotrienes apart from the many known pathophysiologic actions related to allergy and inflammation. (Blood. 2001;97:3433-3440)..
  33. ncbi A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma
    Claudia R Morris
    Department of Emergency Medicine, Children s Hospital and Research Center, Oakland, California 94609, USA
    Ann Allergy Asthma Immunol 104:161-71. 2010
    ..In adults, intravenous montelukast added to standard therapy significantly improved forced expiratory volume in 1 second (FEV1) and reduced hospital admissions compared with standard therapy alone...
  34. ncbi The role of decongestants, cromolyn, guafenesin, saline washes, capsaicin, leukotriene antagonists, and other treatments on rhinitis
    Nataliya M Kushnir
    Allergy and Immunology Clinic of East Bay, 2320 Woolsey Street 314, Berkeley, CA 94705, USA
    Immunol Allergy Clin North Am 31:601-17. 2011
    ..This article provides an overview of treatment suggestions, benefits, and side effects for available OTC, prescription drug, and alternative choices in addition to the therapies described in other articles...
  35. ncbi A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis
    Hans Bisgaard
    Copenhagen Studies on Asthma in Childhood COPSAC, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Am J Respir Crit Care Med 167:379-83. 2003
    ..04). Exacerbations were significantly delayed from montelukast compared with placebo (p < 0.05). In conclusion, cys-LT antagonist treatment reduces lung symptoms subsequent to RSV bronchiolitis...
  36. ncbi Characterization of the human cysteinyl leukotriene 2 receptor
    C E Heise
    Department of Pharmacology, University of Virginia, School of Medicine, Charlottesville, Virginia 22908, USA
    J Biol Chem 275:30531-6. 2000
    ....
  37. pmc Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists
    Elizabeth A Mellor
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Exp Med 195:583-92. 2002
    ....
  38. ncbi Antileukotriene drugs: clinical application, effectiveness and safety
    G Riccioni
    Department of Biomedical Science, Faculty of Medicine and Surgery, University G D Annunzio, Chieti, Italy
    Curr Med Chem 14:1966-77. 2007
    ..The aim of this review is to show the most recent applications and effectiveness in clinical practice of the LTRAs...
  39. ncbi Reports of suicidality in clinical trials of montelukast
    George Philip
    Merck and Co, Inc, North Wales, PA 19454, USA
    J Allergy Clin Immunol 124:691-6.e6. 2009
    ..In recent years, a number of drugs and drug classes have come under scrutiny by the US Food and Drug Administration regarding suicidality (including suicidal behavior and ideation)...
  40. ncbi The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old
    Daniel A Straub
    Division of Respiratory Medicine, University Children s Hospital, Steinwiesstrasse 75, CH 8032 Zurich, Switzerland
    Chest 127:509-14. 2005
    ..The study was undertaken to investigate the influence of once-daily treatment with montelukast (Singulair; MSD; Glattbrugg, Switzerland) on levels of exhaled nitric oxide (eNO) and lung function in preschool children with asthma...
  41. ncbi Ribavirin and cysteinyl leukotriene-1 receptor blockade as treatment for severe bronchiolitis
    Cynthia A Bonville
    Department of Pediatrics, State University of New York Upstate Medical University, 750 East Adams Street, Syracuse, New York 13210, USA
    Antiviral Res 69:53-9. 2006
    ..01). These findings define further the independent contributions made by virus replication and by the ensuing inflammatory response to the detrimental sequelae of pneumovirus infection in vivo...
  42. ncbi Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children
    Hans Bisgaard
    Danish Pediatric Asthma Center, Department of Pediatrics, Copenhagen University Hospital, Gentofte, DK 2900 Copenhagen, Denmark
    Am J Respir Crit Care Med 178:854-60. 2008
    ..Am J Respir Crit Care Med 2003;167:379-383) reported the efficacy of montelukast in post-respiratory syncytial virus (RSV) bronchiolitic respiratory symptoms...
  43. ncbi Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective
    N Nathani
    Department of Thoracic Medicine, City Hospital, Dudley Road, Birmingham B18 7QH, UK
    Thorax 63:883-8. 2008
    ..b>Leukotriene antagonists (LTAs) are used in the management of asthma and may facilitate a reduction in steroid dosage...
  44. ncbi Role of leukotrienes in asthma pathophysiology
    H Bisgaard
    Department of Pediatrics, National University Hospital, Rigshospitalet, Copenhagen, Denmark
    Pediatr Pulmonol 30:166-76. 2000
    ..The bronchodilator properties of CysLTRAs seem to be additive to those of beta(2)-agonists and corticosteroids. These data suggest that CysLTs are important therapeutic targets in the management of inflammation in asthma...
  45. ncbi Leukotriene antagonists as first-line or add-on asthma-controller therapy
    David Price
    Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom
    N Engl J Med 364:1695-707. 2011
    ..Most randomized trials of treatment for asthma study highly selected patients under idealized conditions...
  46. ncbi Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years
    B Knorr
    Departments of Pulmonary Immunology, Epidemiology, and Biostatistics, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    Pediatrics 108:E48. 2001
    ....
  47. ncbi Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling
    Stephen T Holgate
    Respiratory, Cell, and Molecular Biology Research Division, University of Southampton School of Medicine, Southampton, UK
    J Allergy Clin Immunol 111:S18-34; discussion S34-6. 2003
    ....
  48. pmc Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids
    Robert F Lemanske
    University of Wisconsin School of Medicine and Public Health, Madison, USA
    N Engl J Med 362:975-85. 2010
    ..For children who have uncontrolled asthma despite the use of low-dose inhaled corticosteroids (ICS), evidence to guide step-up therapy is lacking...
  49. ncbi Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children
    H Bisgaard
    Department of Pediatrics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Am J Respir Crit Care Med 162:187-90. 2000
    ..The bronchoprotection appeared to be homogeneous among the children, and seemed independent of steroid treatment. This suggests that LTRAs may be of therapeutic use in limiting clinical symptoms of asthma in young children...
  50. ncbi Cedar and cypress pollinosis and allergic rhinitis: quality of life effects of early intervention with leukotriene receptor antagonists
    Keita Sasaki
    Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba 260 8670, Japan
    Int Arch Allergy Immunol 149:350-8. 2009
    ..Allergic rhinitis involves inflammation of the nasal passages. The use of nasal steroids is generally very effective in providing significant symptom relief. However, compliance for their use is sometimes poor...
  51. pmc Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing
    Leonard B Bacharier
    Department of Pediatrics, Washington University and St Louis Children s Hospital, St Louis, MO 63110, USA
    J Allergy Clin Immunol 122:1127-1135.e8. 2008
    ..Acute wheezing illnesses in preschoolers require better management strategies to reduce morbidity...
  52. ncbi Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism
    Chizu Fukushima
    Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan
    Int Arch Allergy Immunol 136:165-72. 2005
    ..The aim of this study was to determine the mechanism of pranlukast-induced interleukin-5 (IL-5) inhibition in allergic inflammation...
  53. ncbi Leukotrienes as mediators of asthma
    S Nicosia
    Laboratory of Molecular Pharmacology, Institute of Pharmacological Sciences, University of Milan, Via Balzaretti, Milan, 9 20133, Italy
    Pulm Pharmacol Ther 14:3-19. 2001
    ..Finally, the evidence supporting their role as asthma mediators is reviewed, including the effects of anti LT drugs (both biosynthesis inhibitors and receptor antagonists) in experimental and clinical asthma...
  54. ncbi Inverse agonist activity of selected ligands of the cysteinyl-leukotriene receptor 1
    Denis J Dupre
    Immunology Division, Department of Pediatrics, Faculty of Medicine, Universite de Sherbrooke, Sherbrooke, Quebec, J1H 5N4 Canada
    J Pharmacol Exp Ther 309:102-8. 2004
    ..We demonstrate here that Montelukast, MK571, and Zafirlukast can act as inverse agonists on the human CysLT(1) receptor...
  55. ncbi Cysteinyl leukotriene-1 receptor activation in a human bronchial epithelial cell line leads to signal transducer and activator of transcription 1-mediated eosinophil adhesion
    Mirella Profita
    Institute of Biomedicine and Molecular Immunology, Italian National Research Council, Palermo, Italy
    J Pharmacol Exp Ther 325:1024-30. 2008
    ..Effective CysLT(1)R antagonism may therefore contribute to the control of the chronic inflammatory condition that characterizes human airways in asthma...
  56. ncbi Pranlukast regulates tumour growth by attenuating IL-4 production in Kimura disease
    Yoshikazu Ohtsuka
    Department of Paediatrics, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo ku, 113 8421 Tokyo, Japan
    Eur J Pediatr 163:416-7. 2004
  57. ncbi Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia
    Craig A Friesen
    Section of Gastroenterology, The Children s Mercy Hospital and Clinics, Kansas City, Missouri 64108, USA
    J Pediatr Gastroenterol Nutr 38:343-51. 2004
    ..We evaluated the effect of this drug in children with eosinophilic duodenitis, defined histologically as duodenal mucosa with peak eosinophil count of more than 10 eosinophils/hpf...
  58. ncbi Leukotriene pathway genetics and pharmacogenetics in allergy
    N P Duroudier
    Division of Therapeutics and Molecular Medicine, University of Nottingham, Nottingham, UK
    Allergy 64:823-39. 2009
    ..The aim of this review was to summarize the recent advances in the knowledge of these important mediators, focusing on genetic and pharmacogenetic aspects in the context of allergic phenotypes...
  59. ncbi Use of montelukast as steroid-sparing agent for recurrent eosinophilic gastroenteritis
    D A Schwartz
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Dig Dis Sci 46:1787-90. 2001
    ..To our knowledge, this is the first use of montelukast as a steroid sparing agent for eosinophilic gastroenteritis...
  60. ncbi Inhibition of human eosinophil activation by a cysteinyl leukotriene receptor antagonist (pranlukast; ONO-1078)
    Masato Suzuki
    Department of Pediatrics, Gunma University School of Medicine, Maebashi, Gunma, Japan
    J Asthma 40:395-404. 2003
    ....
  61. ncbi Pranlukast inhibits NF-kappa B activation in human monocytes/macrophages and T cells
    T Ichiyama
    Department of Pediatrics, Yamaguchi University School of Medicine, Yamaguchi and ONO Pharmaceutical Co Ltd, Osaka, Japan
    Clin Exp Allergy 33:802-7. 2003
    ..Pranlukast inhibits contraction of the tracheal muscle, and thereby antagonizes the binding of LTC4, LTD4 and LTE4. However, the action of pranlukast on monocytes/macrophages and T cells is unknown...
  62. ncbi Effect of montelukast and MK-886 on hepatic ischemia-reperfusion injury in rats
    Gul Daglar
    Department of Fourth Surgery, Ankara Numune Education and Research Hospital, Ankara, Turkey
    J Surg Res 153:31-8. 2009
    ..MK-886 is an inhibitor of 5-lipoxygenase, and montelukast is a cysteinyl leukotriene receptor antagonist. The aim of this study was to investigate whether MK-886 and montelukast are effective in preventing hepatic I/R injury...
  63. ncbi SCF-induced airway hyperreactivity is dependent on leukotriene production
    S H Oliveira
    Department of Pathology, University of Michigan Medical School, 13012 Catherine, Ann Arbor, MI 48109-0602, USA
    Am J Physiol Lung Cell Mol Physiol 280:L1242-9. 2001
    ..Altogether, these studies indicate that SCF-induced airway hyperreactivity is dependent upon leukotriene-mediated pathways...
  64. ncbi A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis
    Israel Amirav
    Ziv Medical Centre, Department of Pediatrics, Safed 13100, Israel
    Pediatrics 122:e1249-55. 2008
    ..Recently, a specific cysteinyl leukotriene receptor antagonist, montelukast (Singulair [MSD, Haarlem, Netherlands]), has been approved for infants in granule sachets...
  65. ncbi The role of inflammation and anti-inflammatory medication in asthma
    P J Barnes
    National Heart and Lung Institute, Department of Thoracic Medicine, London, UK
    Respir Med 96:S9-15. 2002
    ..For many people asthma is associated with complex therapy; thus treatment developments that simplify asthma treatment are an mportant step forward n asthma management...
  66. ncbi CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients
    Seung Hyun Kim
    Ajou University School of Medicine, Department of Allergy and Rheumatology, Yeongtonggu Wonchondong San 5, Suwon 443 721, Korea
    Pharmacogenomics 8:1143-50. 2007
    ....
  67. pmc Eosinophilic oesophagitis: a novel treatment using Montelukast
    S E A Attwood
    Department of Upper Gastro Intestinal Surgery, Hope Hospital, Salford Royal Hospitals NHS Trust, Manchester, UK
    Gut 52:181-5. 2003
    ..This is essential for histological diagnosis. To date, treatment success has been achieved only with corticosteroids. We describe here the use of an eosinophil stabilising agent Montelukast for the symptomatic relief of these patients...
  68. ncbi Actions of cysteinyl leukotrienes in the enteric nervous system of guinea-pig stomach and small intestine
    Sumei Liu
    Department of Physiology and Cell Biology, The Ohio State University, College of Medicine and Public Health, 304 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA
    Eur J Pharmacol 459:27-39. 2003
    ..The receptor mediating these effects was distinct from currently recognized cysteinyl leukotriene receptor subtypes (CysLT(1) and CysLT(2) receptors) and may represent a new receptor subtype...
  69. ncbi Inflammatory cells in asthma: mechanisms and implications for therapy
    Qutayba Hamid
    Meakins Christie Laboratories, McGill University, Montreal, Quebec, Canada
    J Allergy Clin Immunol 111:S5-S12; discussion S12-7. 2003
    ..Eosinophils may be targets for various pharmacologic activities of leukotriene receptor antagonists through their ability to downregulate a number of events that may be key to the effector function of these cells...
  70. ncbi Montelukast: use in pediatric patients with eosinophilic gastrointestinal disease
    Jon A Vanderhoof
    J Pediatr Gastroenterol Nutr 36:293-4. 2003
  71. ncbi Pathophysiological role of mast cells in collagen-induced arthritis: study with a cysteinyl leukotriene receptor antagonist, montelukast
    Naotaka Shiota
    Department of Pharmacology, Shimane University School of Medicine, 89 1 Enya cho, Izumo, Shimane 693 8501, Japan
    Eur J Pharmacol 548:158-66. 2006
    ..Montelukast may lead to a beneficial therapeutic effect by inhibiting TNF-alpha production by mast cells...
  72. ncbi Effect of montelukast compared with inhaled fluticasone on airway inflammation
    S E Overbeek
    Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands
    Clin Exp Allergy 34:1388-94. 2004
    ..Inhaled corticosteroids are currently regarded as the gold standard in anti-inflammatory therapy, however, leukotriene receptor antagonists have been ascribed anti-inflammatory properties...
  73. ncbi The effect of montelukast on soluble interleukin-2 receptor and tumor necrosis factor alpha in pediatric asthma
    Murat Can
    Department of Biochemistry, Karaelmas University of Medicine, Zonguldak, Turkey
    Allergy Asthma Proc 27:383-6. 2006
    ..674; p < 0.01). This study indicates that montelukast improves clinical parameters and shows anti-inflammatory response by decreasing serum sIL-2R and TNF-alpha levels...
  74. ncbi Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends
    Valerie Capra
    Department of Pharmacological Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy
    Med Res Rev 27:469-527. 2007
    ....
  75. ncbi Effects of leukotriene receptor antagonists on monocyte chemotaxis, p38 and cytoplasmic calcium
    Chih Hsing Hung
    Department of Pediatrics, Tri Service General Hospital, National Defense Medical Center, Taipei, and Department of Pediatrics, Faculty of Pediatrics, College of Medicine, Kaohsiung Medical University, Taiwan, Republic of China
    Pediatr Allergy Immunol 17:250-8. 2006
    ..These data demonstrate that montelukast is effective in down-regulating human monocyte chemotaxis induced by MCP-1. This effect may involve the down-regulation of MCP-1-induced [Ca2+]i and p38 MAPK expression...
  76. ncbi Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma
    Robert S Zeiger
    Department of Pediatrics, University of California San Diego, San Diego, CA 92111, USA
    J Allergy Clin Immunol 117:45-52. 2006
    ..Outcome data are needed to base recommendations for controller asthma medication use in school-aged children...
  77. ncbi Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules
    Shinji Maeba
    Department of Pediatrics, Yamaguchi University School of Medicine, Yamaguchi, Japan
    Ann Allergy Asthma Immunol 94:670-4. 2005
    ..Montelukast is known as a cysteinyl leukotriene 1 receptor antagonist. However, the action of montelukast in terms of nuclear factor KB (NF-kappaB) activation and the production of proinflammatory molecules is unknown...
  78. ncbi Montelukast treatment does not affect peripheral blood neutrophil functions in asthma patients
    R Levy
    Pulmonary Unit, Infectious Diseases Laboratory, Faculty of Health Sciences, Soroka University Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel
    Respiration 71:37-44. 2004
    ..Leukotriene receptor antagonists have become an integral part of asthma treatment as an add-on therapy for patients with moderate disease activity...
  79. ncbi A review of montelukast in the treatment of asthma and allergic rhinitis
    Anjuli Nayak
    Department of Pediatrics, University of Illinois College of Medicine, Peoria, Illinois 61603, USA
    Expert Opin Pharmacother 5:679-86. 2004
    ..Clinical trials have shown that montelukast is effective and safe in the treatment of patients with asthma, allergic rhinitis or both diseases...
  80. ncbi Inhaled corticosteroids versus leukotriene antagonists as first-line therapy for asthma: a systematic review of current evidence
    Francine M Ducharme
    Department of Paediatrics, The Montreal Children s Hospital, McGill University Health Centre, 2300 Tupper Street Room C 538, Montreal, Quebec H3H 1P3, Canada
    Treat Respir Med 3:399-405. 2004
    ..In conclusion, the scientific evidence does not support the substitution of leukotriene receptor antagonists for low doses of inhaled corticosteroids, which should remain first-line therapy for asthma control...
  81. pmc Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma
    Graeme P Currie
    Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
    Br J Clin Pharmacol 56:422-6. 2003
    ..Our aim is to evaluate whether responsiveness to leukotriene receptor antagonists was determined by expression of the variant (C) or wild-type (A) polymorphism of this enzyme...
  82. ncbi Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma
    Graeme P Currie
    Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, Scotland, UK
    Am J Respir Crit Care Med 167:1232-8. 2003
    ..Further studies are required to evaluate whether these effects of montelukast translate into clinical benefits...
  83. ncbi Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma
    J C Adkins
    Adis International Limited, Auckland, New Zealand
    Drugs 55:121-44. 1998
    ..The rationale for the development of leukotriene antagonists was based on in vitro and in vivo data demonstrating the extensive role of the cysteinyl leukotrienes C4 (..
  84. ncbi Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial
    D S Robinson
    Allergy and Clinical Immunology, Imperial College School of Medicine at the National Heart and Lung Institute, London SW3 6LY, UK
    Lancet 357:2007-11. 2001
    ..We aimed to assess whether montelukast, a leukotriene receptor antagonist, can improve symptoms or lung function in patients with chronic asthma with symptoms already taking corticosteroids...
  85. ncbi Discovery of leukotrienes and development of antileukotriene agents
    A R Leff
    The University of Chicago, Illinois 60637, USA
    Ann Allergy Asthma Immunol 86:4-8. 2001
    ..After reading this article, readers should have an understanding of the chemical mediators involved in the pathogenesis of asthma, the structural features of LTs, and the role of anti-LTs in the management of asthma symptoms...
  86. ncbi Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial
    W Busse
    University of Wisconsin Hospital and Clinics, H6 367 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792 2454, USA
    J Fam Pract 50:595-602. 2001
    ..The objective of our study was to compare the efficacy and safety of fluticasone propionate (an inhaled corticosteroid) with zafirlukast (a leukotriene modifier) for persistent asthma...
  87. ncbi Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast
    Kenji Minoguchi
    First Department of Internal Medicine, Showa University, School of Medicine, Tokyo, Japan
    Chest 121:732-8. 2002
    ..We examined the effects of a cysteinyl LT 1-receptor antagonist, montelukast, on sputum eosinophil levels, and the correlation between sputum eosinophils and bronchodilatation in patients with asthma...
  88. ncbi Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age
    Richard B R Muijsers
    Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, New Zealand
    Paediatr Drugs 4:123-39. 2002
    ..Montelukast is generally well tolerated. The frequency of adverse events in montelukast-treated children of all ages was comparable to that in patients receiving placebo...
  89. ncbi Regulation of leukotrienes in the management of asthma: biology and clinical therapy
    A R Leff
    Department of Medicine MC6076, Section of Pulmonary and Critical Care Medicine, University of Chicago, 5841 South Maryland Avenue, Chicago, Illinois 60637, USA
    Annu Rev Med 52:1-14. 2001
    ..In the past year, the high-affinity cysLT receptor has been cloned. This holds forth the promise of a second generation of LTRA agents of even greater efficacy and possibly greater duration of action...
  90. ncbi Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids
    A M Wilson
    Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, UK
    Chest 119:1021-6. 2001
    ..CONCLUSIONS: Montelukast and salmeterol exhibited significant improvements in asthma control when given as second-line therapy. Montelukast also produced significant effects on AMP challenge and EOS suggesting anti-inflammatory activity...
  91. ncbi Prostaglandins and leukotrienes: advances in eicosanoid biology
    C D Funk
    Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Science 294:1871-5. 2001
    ..Important insights into the mechanisms of inflammatory responses, pain, and fever have been gleaned from our current understanding of eicosanoid biology...
  92. ncbi Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist
    H P Nothacker
    Department of Pharmacology, University of California at Irvine, Irvine, California, USA
    Mol Pharmacol 58:1601-8. 2000
    ..Moreover, we have identified BAY u9773 as a CysLT(2) selective agonist, which could prove to be of immediate use in understanding the functional roles of the CysLT(2) receptor...
  93. ncbi The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions
    M P Berges-Gimeno
    Hospital Ramon y Cajal, Madrid, Spain
    Clin Exp Allergy 32:1491-6. 2002
    ..Leukotrienes (LTs) appear to be crucial mediators of aspirin (ASA)-induced lower respiratory tract reactions. Therefore, it is logical to assume that leukotriene-modifier drugs (LTMDs) might block these reactions...
  94. pmc Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells
    E A Mellor
    Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 98:7964-9. 2001
    ....
  95. pmc Eosinophilic oesophagitis: treatment using Montelukast
    R Sinharay
    Gut 52:1228-9. 2003
  96. ncbi Leukotriene antagonists and the Churg-Strauss syndrome
    Ghassan Jamaleddine
    Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Semin Arthritis Rheum 31:218-27. 2002
    b>Leukotriene antagonists (LTAs), or antileukotrienes, are a new group of anti-inflammatory drugs used for the treatment of asthma. They might substitute for or allow tapering of corticosteroids in asthmatic patients...
  97. ncbi Leukotriene antagonists: bystanders or causes of Churg-Strauss syndrome?
    Alfonse T Masi
    Semin Arthritis Rheum 31:211-7. 2002
  98. ncbi Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma
    H Bisgaard
    Department of Paediatrics, University Hospital of Copenhagen, Cophenhagen, Denmark
    Allergy 56:7-11. 2001
    ..Moreover, the bronchodilator properties of the leukotriene receptor antagonists are additive with those of beta agonists. These data provide strong support for the use of leukotriene receptor antagonists for treating asthma...
  99. ncbi Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture
    Brian E Daikh
    University of Rochester Strong Memorial Hospital Divisions of Allergy, Immunology, and Rheumatology, Rochester, New York, USA
    Ann Allergy Asthma Immunol 90:23-7. 2003
    ..Limited results have been achieved with oral cromolyn, ketotifen, and other antihistamines. Oral corticosteroids are effective, but long-term use is complicated by side effects including growth retardation, diabetes, and osteoporosis...
  100. ncbi Leukotriene-receptor antagonists
    B J Lipworth
    Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, UK
    Lancet 353:57-62. 1999
    ..Here I overview the clinical pharmacology of leukotriene antagonists and appraise the published data from clinical trials, and look at the appropriate position of these ..
  101. ncbi Anti-inflammatory and lung function effects of montelukast in asthmatic volunteers exposed to sulfur dioxide
    H Gong
    Environmental Health Service, Rancho Los Amigos, National Rehabilitation Center, Downey, CA 90242, USA
    Chest 119:402-8. 2001
    ..Some asthma medications mitigate the SO(2) response, which is not fully understood but appears to involve multiple mechanisms...

Research Grants62

  1. Development of Montelukast Delivery System for Childhood Asthma
    Je Phil Ryoo; Fiscal Year: 2013
    ..Upon completion of the PK and irritation studies, we will file IND to initiate the phase I clinical trial to prove safety and detrmine best dose for NAL6336 ODF. ..
  2. Regulation of Allergic Asthma by TGF-beta-induced Modulation of mMCP-1 and mMCP-4
    APARNA BALA SUNDARAM; Fiscal Year: 2013
    ..also plays a key role in exacerbating allergic asthma, and is the therapeutic target of both leukotriene antagonists and anti-IgE antibodies...
  3. CONFERENCE ON EICOSANOID LIPID MEDIATORS
    William Smith; Fiscal Year: 2001
    ..Importantly, the Keystone Symposium format provides an open, congenial setting for graduate students and postdoctoral fellows to interact with senior researchers in the eicosanoid area. ..
  4. Modification of Allergic Immunologic Response by Leukot
    Patricia Finn; Fiscal Year: 2004
    ..Aim 2 will investigate changes in the immunoregulation of costimulatory ligands, CD80, CD86 and B7-h. Aim 3 will identify differentially expressed T lymphocyte genes using expression array analysis. ..
  5. AIRWAY INFLAMMATION IN EXERCISE-INDUCED ASTHMA
    TEAL HALLSTRAND; Fiscal Year: 2004
    ..inflammation and the development of a late airway response to exercise; 4) to determine the role of leukotriene antagonists and corticosteroids in the management of the late phase of exercise-induced asthma...
  6. Severe Asthma From Respiratory Infections
    William W Busse; Fiscal Year: 2010
    ..These studies will provide new insights into the mechanisms of asthma, particularly severe disease, and possibilities of new approaches to treatment. ..
  7. MECHANISMS OF RHINOVIRUS INDUCED ASTHMA
    William Busse; Fiscal Year: 2002
    ..The proposed studies will provide new evidence as the mechanisms by which RV-infected epithelial cells cause granulocytic bronchial inflammation and asthma exacerbations. ..
  8. EICOSANOIDS AND LUNG MACROPHAGE ANTIMICROBIAL MECHANISMS
    Marc Peters Golden; Fiscal Year: 2008
    ..EP4 ligation. These proposed studies will provide fundamental insights into AM antimicrobial function, and a clinically relevant framework for understanding and modulating innate immunity in the lung. ..
  9. MECHANISMS OF AIRWAY HYPERRESPONSIVENESS
    Alan Leff; Fiscal Year: 2005
    ..Data derived from these studies will elucidate potential cell-cell interaction as well as newly defined mechanisms regulating synthesis of bronchoactive eicosanoids. ..
  10. PHARMACOGENETICS OF ASTHMA MONOTHERAPY
    John Lima; Fiscal Year: 2005
    ..The results of this pharmacogenetic study may facilitate the optimal selection of monotherapy in asthma. ..
  11. Transcellular Communication in Airway Inflammation and Airway Hyperresponsiveness
    ALAN RICHARD LEFF; Fiscal Year: 2010
    ..Data derived from these studies should elucidate a new endogenous mechanism of transcellular communication that initiates airway inflammation and AHR. ..
  12. CYTOKINE DYSREGULATION, VIRUSES, AND CHILDHOOD ASTHMA
    ROBERT LEMANSKE; Fiscal Year: 2001
    ..The results of these studies will provide information that will be a major step forward in our understanding of the relative influence that genetic and environmental risk factors on the development of childhood asthma. ..
  13. Treatment of Severe Persistent Asthma
    ROBERT LEMANSKE; Fiscal Year: 2007
    ..abstract_text> ..
  14. Improving Follow-up After an Emergency Visit for Asthma
    Joseph Zorc; Fiscal Year: 2007
    ..The expected goal of the project will be to develop an intervention that can subsequently be tested in a newly developed, federally-funded research network of pediatric EDs. ..
  15. LEUKOTRIENE POLYMORPHISMS & MONTELUKAST RESPONSE
    John Lima; Fiscal Year: 2003
    ..b>Leukotriene antagonists are thought to be the most innovative approach to asthma therapy in 20 years...
  16. CARE Network - Madison Clinical Center
    ROBERT LEMANSKE; Fiscal Year: 2008
    ..abstract_text> ..
  17. CARE Network-UCSD Clinical Center
    Robert Zeiger; Fiscal Year: 2008
    ..abstract_text> ..
  18. ASTHMA CLINICAL RESEARCH NETWORK
    ROBERT LEMANSKE; Fiscal Year: 2002
    ....
  19. Lymphocyte homing to the spleen
    MITCHELL GRAYSON; Fiscal Year: 2005
    ..Identification of mechanisms controlling entry of lymphocytes into the lymphoid compartment of the spleen will provide new targets for immunomodulatory drug therapy. ..
  20. T Regulatory Cells and Childhood Asthma
    James Gern; Fiscal Year: 2008
    ..abstract_text> ..
  21. An interdisciplinary and integrative study of tendinopathy
    James H C Wang; Fiscal Year: 2010
    ....
  22. Exercise as an Anti-Inflammatory Therapy for Asthma
    John Mastronarde; Fiscal Year: 2007
    ..These results will have a major impact in defining the role of exercise therapy in the treatment of asthma, which may be revealed as a "new" anti-inflammatory treatment for asthma. ..
  23. CysLt and P2Y Receptors and Lung Inflammation
    Joshua Boyce; Fiscal Year: 2007
    ..abstract_text> ..
  24. Micellar VIP Nanoparticles for Rheumatoid Arthritis
    Israel Rubinstein; Fiscal Year: 2007
    ..abstract_text> ..
  25. The Reliability of the Placebo Effect in Asthma
    Michael Wechsler; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  26. Clinical Trial of Acid Reflux Therapy in Asthma
    Robert Wise; Fiscal Year: 2007
    ..Pre-specified subgroup analyses will be conducted to determine if there are clinical or demographic characteristics that predict benefit from treatment of GERD in asthma. ..
  27. Lipid Mediators in the Resolution of Asthma Exacerbations
    Bruce Levy; Fiscal Year: 2008
    ..This proposal's specific aims are directed towards uncovering basic mechanisms in the pathobiology of resolution from asthma exacerbation. ..
  28. 5-LIPOXYGENASE PRODUCTS IN ASTHMATIC IMMUNE RESPONSE
    William Henderson; Fiscal Year: 2008
    ..abstract_text> ..
  29. ASTHMA CLINICAL RESEARCH NETWORK
    William Calhoun; Fiscal Year: 2008
    ..Pitt strongly supports collaborative, clinical network research. Data from the DART and ESTA trials can help to improve the care of patients with asthma. ..
  30. Platelet-Derived Growth Factor, Remodeling and Asthma
    Monica Kraft; Fiscal Year: 2010
    ..This proposal will also determine whether PDGF inhibition could provide important adjuvant therapy for the treatment of severe asthmatics by limiting structural changes that result from activity of this pathway. ..
  31. The contribution of heat shock/stress pathways to acute lung injury
    Jeffrey D Hasday; Fiscal Year: 2010
    ..Ablating fever may eliminate its beneficial as well as its harmful effects. We expect that a better understanding of its molecular mechanisms will allow us to selectively block the harmful effects of fever/hyperthermia. ..
  32. NOVEL METHODS OF GENE THERAPY FOR LIVER DISEASE
    Timothy Davern; Fiscal Year: 2002
    ....
  33. Childhood Asthma Research and Education Network: Denver Site
    Stanley Szefler; Fiscal Year: 2008
    ..End of abstract.) [unreadable] [unreadable]..
  34. Regulation of Pulmonary Host Defense by Leptin
    Peter Mancuso; Fiscal Year: 2010
    ..They will also test the use of exogenous leptin as an adjunctive therapeutic agent in the treatment of pneumococcal pneumonia. ..
  35. Mechanisms of HSF1-mediated Repression of TNF-alpha
    Jeffrey Hasday; Fiscal Year: 2007
    ..The proposed studies will provide new insight into how the biochemical events that regulate host defenses is modified by the temperature increase that occurs during fever. ..
  36. A Request for support of 25th SPRSM Meeting
    James Wang; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  37. BODY TEMPERATURE AND REGULATING HOST DEFENSES
    Jeffrey Hasday; Fiscal Year: 2001
    ..abstract_text> ..
  38. SCLERODERMA LUNG STUDY
    Robert Wise; Fiscal Year: 2003
    ..abstract_text> ..
  39. BIOCHEMISTRY/BIOLOGY OF 5-LIPOXYGENASE AND LEUKOTRIENES
    COLIN FUNK; Fiscal Year: 2003
    ..New insights into the pathophysiologic sequelae of leukotrienes in asthma and ultimately better treatments of this disease will be an outcome of these studies. ..
  40. RELATIONSHIP BETWEEN ALLERGIC RHINITIS AND SINUSITIS
    Fuad Baroody; Fiscal Year: 2003
    ..This will hopefully help to improve our therapeutic modalities for this enigmatic illness that affects millions of Americans every year. ..
  41. IMMUNOPATHOGENESIS OF ALLERGIC ASPERGILLOSIS
    RAYMOND SLAVIN; Fiscal Year: 2003
    ..abstract_text> ..
  42. Keystone Symposium: Eicosanoid Lipid Mediators
    Jilly Evans; Fiscal Year: 2003
    ..NIH support for this meeting will allow more graduate student and postdoctoral participation in.this exciting multidisciplinary meeting. ..
  43. NOVEL LUNG DERIVED CHALONES--BIOSYNTHESIS AND BIOACTIONS
    Bruce Levy; Fiscal Year: 2002
    ..End of Abstract) ..
  44. Agilent 5973 GC/MS System
    GARY MOLANDER; Fiscal Year: 2002
    ..Our current lack of such instrumentation negatively affects the ability to carry out many of these studies. This critical capability, in the form of an instrument for everyday analysis, is urgently needed. ..
  45. ASTHMA AND EXPOSURE TO PEAKS IN PARTICULATE AIR POLLUT
    RALPH DELFINO; Fiscal Year: 2001
    ..This research is expected to have an impact on decisions regarding the protection of health in populations frequently exposed to higher particle excursions. ..
  46. IMMUNOPATHOGENESIS OF ALLERGIC ASPERGILLOSIS
    RAYMOND SLAVIN; Fiscal Year: 2001
    ....
  47. Biology of Single Activity PGH Synthases
    COLIN FUNK; Fiscal Year: 2004
    ..Results obtained from this proposal should have broad implications for understanding mechanisms of human cancer and inflammatory disease. ..
  48. RECOMBINANT HUMAN INTERLEUKIN-4 RECEPTOR IN ASTHMA
    Larry Borish; Fiscal Year: 2004
    ..We hypothesize that individuals who are genetically predisposed to either increased IL-4 production or IL-4 responsiveness will represent a cohort more likely to benefit from the IL-4 antagonists. ..
  49. Defective PS Exposure in Neutrophil Apoptosis in CGD
    Donna Bratton; Fiscal Year: 2007
    ..It is expected that data from this investigation will identify novel potential therapeutic targets to address disordered inflammation of CGD. ..
  50. Chemogenomics to Identify New Molecular Targets in PF
    William Henderson; Fiscal Year: 2006
    ..These studies represent a focused effort using chemogenomics to identify, develop, and validate small molecule inhibitors of AP-1/TGFBeta-driven profibrotic gene expression as novel therapies in PF patients. ..
  51. The Role of Mast Cells in Lung Inflammation
    Joshua Boyce; Fiscal Year: 2006
    ..These studies, carried out in non-transformed hPrMC and hMC, have potential implications for the control of hMC distribution and effector function in asthma. ..
  52. Pediatric Asthma, Particulate Air Pollution and NO2
    RALPH DELFINO; Fiscal Year: 2006
    ..Long-term goals are to improve knowledge about the independent and combined adverse effects of particulate and gaseous air pollutants by examining acute exposures and responses using ambulatory monitoring methods. ..
  53. The Placebo Effect in Asthma
    Robert Wise; Fiscal Year: 2005
    ..Understanding the placebo response can lead to improvements in research and treatment of asthma. ..
  54. Improving Physician Adherence to Asthma Guidelines
    Gregory Diette; Fiscal Year: 2005
    ..usual generalist care; and 3) How care should be organized for management of chronic diseases. ..
  55. Mechanisms of Steroid Resistance in Severe Asthma
    William Calhoun; Fiscal Year: 2005
    ..abstract_text> ..
  56. AADRC -- Mechanisms of Virus-Induced Asthma
    James Gern; Fiscal Year: 2005
    ..It is proposed that these collaborative studies will provide new insight into mechanisms of respiratory-virus-induced asthma, the possible role of diminished IFN-gamma production in this process, and possibilities for new treatment...
  57. Polymorphisms of Neural NOS and the Asthma Phenotype
    Michael Wechsler; Fiscal Year: 2005
    ....
  58. Catalytic Processes for Selective Organic Synthesis
    GARY MOLANDER; Fiscal Year: 2005
    ..4) Carbometalation/cyclization reactions will be explored utilizing organochromium species. 5) Ligands and catalytic systems designed for asymmetric synthesis will be explored. ..
  59. Oxidative Stress and Anti-Inflammatory Lipids in Airway Disease
    Bruce D Levy; Fiscal Year: 2010
    ..In this proposal, we seek to develop a better understanding of the natural biological processes invoked during airway infection and inflammation that dysregulate the natural homeostatic mechanisms. (End of Abstract) ..
  60. CELLULAR BASIS OF HYPERSENSITIVITY DISEASES IN HUMANS
    FRANK AUSTEN; Fiscal Year: 2007
    ..abstract_text> ..